Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ATR-258 / Atrogi
NCT05409924: First-in-human Single and Multiple Dose Trial of ATR-258	Completed	1	71	Europe	ATR-258, Placebo	Atrogi AB, Key2Compliance, CRS Clinical Research Services	Type 2 Diabetes Mellitus	10/23	10/23
Attractive 2, NCT06432673: The Trial - Pharmacokinetics of ATR-258 Oral Capsule vs. Oral Solution Formulations in Healthy Volunteers	Completed	1	21	Europe	ATR-258 Oral solution, ATR-258 Oral capsule	Atrogi AB	Type2diabetes	05/24	05/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ATR-258 / Atrogi
NCT05409924: First-in-human Single and Multiple Dose Trial of ATR-258	Completed	1	71	Europe	ATR-258, Placebo	Atrogi AB, Key2Compliance, CRS Clinical Research Services	Type 2 Diabetes Mellitus	10/23	10/23
Attractive 2, NCT06432673: The Trial - Pharmacokinetics of ATR-258 Oral Capsule vs. Oral Solution Formulations in Healthy Volunteers	Completed	1	21	Europe	ATR-258 Oral solution, ATR-258 Oral capsule	Atrogi AB	Type2diabetes	05/24	05/24